As Biotechnology businesses, CRISPR Therapeutics AG (NASDAQ:CRSP) and Tiziana Life Sciences PLC (NASDAQ:TLSA), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Tiziana Life Sciences PLC||3||0.00||11.30M||-0.07||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for CRISPR Therapeutics AG and Tiziana Life Sciences PLC.
Table 2 provides us CRISPR Therapeutics AG and Tiziana Life Sciences PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,388,545.67%||-2.6%||-2%|
|Tiziana Life Sciences PLC||390,922,299.87%||0%||0%|
CRISPR Therapeutics AG and Tiziana Life Sciences PLC Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Tiziana Life Sciences PLC||0||0||0||0.00|
CRISPR Therapeutics AG’s upside potential is 10.16% at a $72 consensus price target.
Institutional & Insider Ownership
The shares of both CRISPR Therapeutics AG and Tiziana Life Sciences PLC are owned by institutional investors at 46.8% and 2.82% respectively. About 0.4% of CRISPR Therapeutics AG’s share are held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Tiziana Life Sciences PLC||4.39%||-19.89%||-24.8%||-21.12%||0%||-24.3%|
For the past year CRISPR Therapeutics AG had bullish trend while Tiziana Life Sciences PLC had bearish trend.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.